Sjögren's Syndrome Is Associated With Meibomian Gland Dysfunction
NCT ID: NCT03434106
Last Updated: 2018-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2018-02-10
2018-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Is Sjögren's Syndrome Associated With Meibomian Gland Dysfunction ?
NCT03060005
A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome
NCT02011776
Laser Acupuncture on Dry Eye and Sjögren's Syndrome-related Dry Eye Symptoms (LADESJS)
NCT06780293
AST Combined With 0.05% Cyclosporin Eye Drop Improve Corneal Nerve Density in Patients With SS Dry Eye
NCT06013436
Evaluation of Therapeutic Effect of Bandage Contact Lenses ( BCL) on Dry Eye Caused by Sjogren's Syndrome
NCT02147509
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
primary Sjögren's syndrome
The female patients with primary Sjögren's syndrome receive the Tears Naturale Forte and Liposic.
liposic
Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatmen
Tears Naturale Forte
This medication is used to relieve dry, irritated eyes
secondary Sjögren's syndrome
The female patients with secondary Sjögren's syndrome receive Tears Naturale Forte and Liposic.
liposic
Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatmen
Tears Naturale Forte
This medication is used to relieve dry, irritated eyes
meibomian gland dysfunction
The female patients with meibomian gland dysfunction receive the Tears Naturale Forte and Liposic.
liposic
Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatmen
Tears Naturale Forte
This medication is used to relieve dry, irritated eyes
control
the female had no history of autoimmune disease receive the Tears Naturale Forte and Liposic.
liposic
Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatmen
Tears Naturale Forte
This medication is used to relieve dry, irritated eyes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
liposic
Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatmen
Tears Naturale Forte
This medication is used to relieve dry, irritated eyes
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with primary SS fulfilled the criteria established by the European Study Group
* Patients with SLE and RA met the criteria set by the American College of Rheumatology
Exclusion Criteria
45 Years
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LanZhou University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jingmin Yuan, MD
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lanzhou University Second Hospital
Lanzhou, Gansu, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018A-005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.